These trials indicated that pembrolizumab significantly improved ORR and extended PFS in patients with driver gene‐negative advanced NSCLC, irrespective of PD‐L1 tumor proportion score (TPS) being ≥50% or ≥1%, compared with chemotherapy alone [115]. This evidence concerns the gene CD274 and neoplasm.